Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.8422
-0.0211 (-2.44%)
At close: Feb 10, 2026, 4:00 PM EST
0.8600
+0.0178 (2.11%)
After-hours: Feb 10, 2026, 7:58 PM EST
Oncolytics Biotech Employees
Oncolytics Biotech had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change
-1
Growth
-3.45%
Revenue / Employee
n/a
Profits / Employee
-$904,312
Market Cap
90.63M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Artiva Biotherapeutics | 106 |
| Precision BioSciences | 67 |
| aTyr Pharma | 65 |
| Biomea Fusion | 42 |
| Equillium | 35 |
| eXoZymes | 31 |
| Cognition Therapeutics | 28 |
ONCY News
- 6 days ago - Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer - GlobeNewsWire
- 26 days ago - Oncolytics Biotech® Announces Results of Special Meeting of Shareholders - GlobeNewsWire
- 26 days ago - Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 4 weeks ago - Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer - GlobeNewsWire
- 4 weeks ago - Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada - GlobeNewsWire
- 4 weeks ago - Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings - Business Wire
- 4 weeks ago - Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris - Business Wire
- 2 months ago - Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer - Business Wire